The Clinical Observation On The Treatment Of LAA Type Ischemic Stroke (Blood Stagnation And Stagnation Evidence) With Huazhuo Hexue Granules

Objective:The study aims to investigate the clinical efficacy and efficacy of Huazhuo hexue Granules on Lp(a)in the therapy of patients with acute stage of LAA ischemic cerebral infarction(Blood turbidity and stasis syndrome).Methods:A total of 90 patients with LAA type ischemic cerelral infarction in the acute stage(Blood turbidity and stasis syndrome)admitted to the Department of Encephalopathy of the Second Affiliated Hospital of Shandong University of Chinese Medicine from December 2021 to December 2022 were randomly divided into control group and treatment group,with 45 cases in each group.Patients who meet the case selection criteria were divided into control group and treatment group by random number table method.The control group was cured with the regimen formulated in the "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018",and the treatment group was additionally treated with Huazhuo hexue Granules on the basis of the "Guidelines 2018".The therapy course of two groups was 14 days,and the observation and follow-up were 30 days.Serum lipids(LDL,sd LDL,Lp(a))and hs-CRP were collected before and after therapy,respectively.NIHSS score was evaluated before treatment and at7,14 and 30 days after treatment.The TCM syndrome rating scale was measured before treatment and 14 days after onset to determine the clinical efficacy.The modified Rankin Scale(m RS)was measured before treatment and 30 days after treatment to determine clinical outcome.Results:1.86 cases were completed in terms of the study protocol,including41 cases of the therapy group and 45 cases ofthe control group.2.Clinical efficacy: The NIHSS score of both groups decreased after7,14 and 30 days of intervention(P<0.05),and the NIHSS score of the treatment group was declined sharply compared with the control group(P<0.05).After 14 days of intervention,blood lipid indexes in both groups were obviously enhanced compared with before intervention(P< 0.05),and blood lipid indexes in the treatment group(LDL,sd LDL,Lp(a))were obviously enhanced compared with the control group(P< 0.05).Compared with before intervention,TCM syndrome scores of the two groups were obviously enhanced at 14 days after intervention(P<0.05),and the therapy group was better than the control group(P<0.05).The efficient was 82.93% in the therapy group and 71.11% in the control group.3.Clinical outcome: The modified Rankin Scale(m RS)score of both groups decreased after 30 days of intervention compared with before intervention(P<O.05),and the clinical outcome of patients in the treatment group was significantly improved compared with the control group(P<O.05).Conclusion:Huazhuo hexue Granules can significantly improve the symptoms of neurological impairment and TCM syndrome in patients with LAA type ischemic stroke in the acute stage(blood stagnation and stagnation evidence),reduce the level of Lp(a),and improve the clinical outcome.The above results indicate that Huazhuo hexue Granules are effective agents for treating acute stage of LAA-type ischemic stroke(blood stagnation and stagnation evidence)and reducing Lp(a)level.